↓ Skip to main content

Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab

Overview of attention for article published in Journal for Immunotherapy of Cancer, January 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)

Mentioned by

twitter
6 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab
Published in
Journal for Immunotherapy of Cancer, January 2018
DOI 10.1186/s40425-018-0318-x
Pubmed ID
Authors

Lorraine Cafuir, David Lawson, Nilesh Desai, Vita Kesner, Alfredo Voloschin

Abstract

Ipilimumab is an FDA-approved anti-CTLA-4 monoclonal antibody used in treatment of metastatic melanoma. We present an unusual neurological complication of Ipilimumab therapy and the diagnostic dilemma it caused. A 42 year old male with Stage IV metastatic melanoma developed lower extremity weakness and sensory neuropathy following three doses of Ipilimumab. MRI of the lumbar spine was initially interpreted as diffuse leptomeningeal disease, and patient began Dexamethasone and radiation with improvement in symptoms. However, subsequent completion imaging revealed smooth nerve root involvement with sparing of the spinal cord, findings more compatible with inflammatory demyelinating polyneuropathy. The absence of malignant cells in the cerebrospinal fluid (CSF) and nerve conduction study (NCS) showing lumbar polyradiculoneuropathy with axonal involvement and demyelinating features supported the diagnosis of inflammatory demyelinating polyneuropathy. Later in the course of his disease, the patient developed frank leptomeningeal melanoma. Ipilimumab immune-related toxicity presented as inflammatory demyelinating polyneuropathy, which was difficult to distinguish from leptomeningeal disease, a common complication of melanoma.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 5 21%
Researcher 4 17%
Other 3 13%
Professor > Associate Professor 2 8%
Student > Master 2 8%
Other 5 21%
Unknown 3 13%
Readers by discipline Count As %
Medicine and Dentistry 13 54%
Neuroscience 3 13%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Computer Science 1 4%
Immunology and Microbiology 1 4%
Other 0 0%
Unknown 4 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 March 2018.
All research outputs
#5,276,353
of 16,669,654 outputs
Outputs from Journal for Immunotherapy of Cancer
#871
of 1,597 outputs
Outputs of similar age
#131,984
of 371,724 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 16,669,654 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,597 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.7. This one is in the 45th percentile – i.e., 45% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 371,724 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them